Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

China National Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Summary

China National Pharmaceutical Group Corp (Sinopharm) is a provider of medical and healthcare services. Its core businesses include the distribution, retailing, research and manufacture of healthcare related products. Its product portfolio includes EPI vaccines; biopharmaceutical products; anaesthetics and psychotropics; anti-infective, anti-tumor, cardiovascular and respiratory system drugs; and medicinal herbs. Its business activities include manufacturing and R&D, pharmaceutical logistics and distribution, pharmacy retail chain, anaesthetic distribution, cold-chain distribution for biological products and medical equipment, and distribution of consumable materials, modern and traditional Chinese medicines, besides medical scientific research, engineering design and pharmaceutical international trade. The company has operations across China. Sinopharm is headquartered in Haidian, Beijing, China.

China National Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

TABLE OF CONTENTS

2
List of Tables 4
List of Figures 6
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 16
Partnerships 16
Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16
Chi-Med Forms Joint Venture with Sinopharm 17
Mitsubishi Forms Joint Venture With Sinopharm 18
China NT Pharma To Form Joint Venture With Sinopharm 18
China State Institute of Pharma Enters Into Research Agreement With Sanofi 19
Aeras Enters Into Co-Development Agreement With China National Biotech Group 20
University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 21
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 22
Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 23
Licensing Agreements 23
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 23
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 24
Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 25
Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 27
Equity Offering 28
Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 28
Sinopharm to Raise USD728 Million in Private Placement of Shares 28
Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 30
Sinopharm Completes Private Placement Of Shares For US$525 Million 30
China National Biotech Plans To Complete IPO For US$1.5 Billion 32
Debt Offering 32
Sinopharm Group Plans Public Offering Of Bonds For US$633 Million 32
China National Biotec Plans Public Offering Of Notes Due 2015 For US$126 Million 33
Sinopharm Group Announces Private Placement Of Medium Term Bonds For US$466 Million 34
Sinopharm Group Completes Private Placement Of Medium Term Bonds For US$308 Million 35
Acquisition 36
China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 36
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 36
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 37
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million 38
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For US$9.8 Million 38
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million 40
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million 41
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 41
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million 42
China National Pharma Acquires 37.1% Stake In Winteam Pharma For US$32.5 Million 43
Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For US$3.3 Million 44
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million 45
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million 46
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million 46
Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For US$33 Million 47
China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For US$1.4 Million 47
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 48
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 49
Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 50
China National Pharmaceutical Group Corp - Key Competitors 52
Key Employees 53
Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List Of Tables

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 1
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
China National Pharmaceutical Group Corp, Deals By Therapy Area, 2011 to YTD 2017 10
China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 16
Chinese Academy of Engineering Wang Guangji Academic Workstation to Enter into Agreement with Changzhou Fangyuan Pharma and China State Institute of Pharmaceutical Industry 16
Chi-Med Forms Joint Venture with Sinopharm 17
Mitsubishi Forms Joint Venture With Sinopharm 18
China NT Pharma To Form Joint Venture With Sinopharm 18
China State Institute of Pharma Enters Into Research Agreement With Sanofi 19
Aeras Enters Into Co-Development Agreement With China National Biotech Group 20
University of Hong Kong Enters Into Research And Development Agreement With China National Pharma 21
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 22
Harbor BioSciences Enters Into Distribution Agreement With China Institute Of Pharma Industry 23
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 23
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 24
Pharming Enters Into Licensing Agreement With Shanghai Institute of Pharma Industry 25
Harbor BioSciences Enters Into Licensing Agreement With China State Institute Of Pharma 27
Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 28
Sinopharm to Raise USD728 Million in Private Placement of Shares 28
Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 30
Sinopharm Completes Private Placement Of Shares For US$525 Million 30
China National Biotech Plans To Complete IPO For US$1.5 Billion 32
Sinopharm Group Plans Public Offering Of Bonds For US$633 Million 32
China National Biotec Plans Public Offering Of Notes Due 2015 For US$126 Million 33
Sinopharm Group Announces Private Placement Of Medium Term Bonds For US$466 Million 34
Sinopharm Group Completes Private Placement Of Medium Term Bonds For US$308 Million 35
China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 36
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 36
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 37
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million 38
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For US$9.8 Million 38
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million 40
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million 41
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 41
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million 42
China National Pharma Acquires 37.1% Stake In Winteam Pharma For US$32.5 Million 43
Beijing Tiantan Biological Products To Sell 13.03% Stake In Beijing Weigu Biological Medicine For US$3.3 Million 44
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million 45
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million 46
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million 46
Shanghai Modern Pharma To Acquire 70% Stake In Jiaozuo Rongsheng Pharma For US$33 Million 47
China National Medicines To Acquire 51% Stake In Beijing-Based Medical Company For US$1.4 Million 47
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 48
China National Pharma Completes Acquisition Of 80.5% Interest In Aurobindo (Datong) Bio Pharma 49
Sinopharm To Acquire 60% Stake In Shijiazhuang Lerentang 50
China National Pharmaceutical Group Corp, Key Competitors 52
China National Pharmaceutical Group Corp, Key Employees 53
China National Pharmaceutical Group Corp, Subsidiaries 54

List Of Figures

China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
China National Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
China National Pharmaceutical Group Corp, Medical Devices Deals, 2011 to YTD 2017 11

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

China National Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market in China 2023

Ulcerative Colitis (UC) Market in China 2023

China National Chemical Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report

China National Electronics Import & Export Corporation - Strategy, SWOT and Corporate Finance Report

FAQs